GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback